country

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P4153

Copy Link Print Information

Enlicitide chloride

(Synonyms: MK-0616 chloride)

Avis client

Based on 1 Customer Validation

Enlicitide chloride is an orally active inhibitor for PCSK9 that blocks the interaction between LPL receptor and PSCK9, with an IC₅₀ of 2.5 nM. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.63%
CAS No.: 2407527-16-4
Formule: C₈₂H₁₁₀ClFN₁₄O₁₅
Masse moléculaire:1586.29

Stockage:

Sealed storage, away from moisture.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Enlicitide chloride Chemical Structure

CAS No.: 2407527-16-4

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- In Vitro
Chemical Information
Solvant et solubilité
- In Vitro
Pureté et documentation
Références
Calculators
Help & FAQs
Bioz

Activité biologique

Description

In Vitro

Enlicitide chloride inhibits the protein-protein interaction between LPL receptor and PCSK9, increases the level of LPL receptor, and thus decreases the level of low-density lipoprotein cholesterol (LDL-C)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 2407527-16-4
Appearance Solid
Masse moléculaire 1586.29
Formule C₈₂H₁₁₀ClFN₁₄O₁₅
Color White to off-white
Synonyms

MK-0616 chloride
Sequence

Ala-{Dpr}-Phe-Trp-Pro-Thr-Tyr-Pro(Covalent bridge:Phe3-Pro5,Ala1-Trp4,Trp4-Pro8,Ala1-Pro8,D-Dpr2)
Sequence Shortening

A-{Dpr}-FWPTYP(Covalent bridge:Phe3-Pro5,Ala1-Trp4,Trp4-Pro8,Ala1-Pro8,D-Dpr2)
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvant et solubilité

In Vitro:

DMSO : 1 mg/mL (0.63 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (281 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Ding FX, et al. Preparation of cyclic peptides as PCSK9 antagonist compounds: World Intellectual Property Organization, WO2019246349. 2019-12-26.

[2]. WHO Drug Information-World Health Organization (WHO).

[3]. Ahamad S, et al., Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment. J Med Chem. 2022 Dec 8;65(23):15513-15539. [Content Brief]

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Obtenir un devis En stock